Quanterix Corporation · NASDAQ:QTRX

Quanterix — Technical Presentation (June 2015)

24 slides from Quanterix's technical presentation, Jun 9, 2015

  1. Slide 1: Homebrew Assay Development Case Studies

    Slide 1: Homebrew Assay Development Case Studies

    Homebrew Assay Development Case Studies: Case 1: A Closer Look at Biomarker Assay Specificity Case 2: Developing a Competitive Biomarker Assay – Work in Progress Elizabeth Dreher & Alison Joyce: Pfizer Inc. Elizabeth.Dreher@Pfizer.com; Alison.Joyce@Pfizer.com June 9th, 2015 Quanterix User Group Meet

  2. Slide 2: Case 1: A Closer Look at Biomarker Assay Specificity

    Slide 2: Case 1: A Closer Look at Biomarker Assay Specificity

    Homebrew Assay Development Case Studies: Case 1: A Closer Look at Biomarker Assay Specificity

  3. Slide 3: Quanterix Simoa Format – Total Biomarker Assay

    Slide 3: Quanterix Simoa Format – Total Biomarker Assay

    Case 1: A Closer Look at Biomarker Assay Specificity Quanterix Simoa Format – Total Biomarker Assay Fluorescent substrate Streptavidin beta-galactosidase  Total biomarker assay: Biotinylated Anti-Drug Ab both free and drug-bound biomarker are measured Forced complex Anti-biomarker Drug  Assay rang

  4. Slide 4: Precision in buffer, in serum matrix

    Slide 4: Precision in buffer, in serum matrix

    Case 1: A Closer Look at Biomarker Assay Specificity Precision in buffer, in serum matrix  %CV of replicates in buffer is excellent, typically < 5%  %CV of replicates in serum matrix is higher, most < 10%  Occasional %CVs > 20%  ~ 4% of replicates per plate  Run duplicates for standard curve, t

  5. Slide 5: Endogenous Biomarker Levels in Individual Normal Serum Donors

    Slide 5: Endogenous Biomarker Levels in Individual Normal Serum Donors

    Case 1: A Closer Look at Biomarker Assay Specificity Endogenous Biomarker Levels in Individual Normal Serum Donors 19/20 normal individual donors scored above the LLOQ (0.28 pg/ml)

  6. Slide 6: Parallelism Analysis of Serum Samples

    Slide 6: Parallelism Analysis of Serum Samples

    Case 1: A Closer Look at Biomarker Assay Specificity Parallelism Analysis Parallelism Analysis of Serum Samples Simoa Total Biomarker Assay Corrected [Biomarker pg/mL] Individual normal human sera did not exhibit parallelism

  7. Slide 7: Immunodepletion with anti-biomarker drug

    Slide 7: Immunodepletion with anti-biomarker drug

    Case 1: A Closer Look at Biomarker Assay Specificity Immunodepletion with anti-biomarker drug Sample % Depletion Eluted Biomarker (pg/mL) Individual 1 0 BLOQ Individual 2* 29 BLOQ Individual 3* 17 BLOQ Individual 4* 34 BLOQ Individual 5 22 BLOQ Individual 6* 0 BLOQ Buffer Spike 97 67.7 Pool Spike 92

  8. Slide 8: Specificity Issues: Detector Troubleshooting

    Slide 8: Specificity Issues: Detector Troubleshooting

    Case 1: A Closer Look at Biomarker Assay Specificity Specificity Issues: Detector Troubleshooting  Detector: mouse mAb against a human Human IgG antibody drug (green) antibodies in serum bound to  Detector: could cross-react with human IgGs beads or capture antibody  non-specific serum signal  T

  9. Slide 9: Specificity Issue: Detector Troubleshooting

    Slide 9: Specificity Issue: Detector Troubleshooting

    Case 1: A Closer Look at Biomarker Assay Specificity Specificity Issue: Detector Troubleshooting Adding anti-hu IgG biotin as detector resulted in significant signal increase in serum only Adding hu IgG significantly blocked signal Biomarker (40 pg/mL) Data suggests:  Detector antibody cross-reacts

  10. Slide 10: Specificity Issue: Comparison of Old v New Detector Conditions

    Slide 10: Specificity Issue: Comparison of Old v New Detector Conditions

    Case 1: A Closer Look at Biomarker Assay Specificity Specificity Issue: Comparison of Old v New Detector Conditions  New buffer reduced non-specific binding by ~50% on average  Old Detector Buffer: 1/20 was BLOQ  New Detector Buffer: 10/20 are BLOQ

  11. Slide 11: Specificity Issue: Rising Above the Noise

    Slide 11: Specificity Issue: Rising Above the Noise

    Case 1: A Closer Look at Biomarker Assay Specificity Specificity Issue: Rising Above the Noise Assay Signal for 3 outliers removed Approach: Sample Individual Donors using ROUT method  Use a statistical 2015 0.354 in GraphPad method to remove 2014 0.021 outliers 2013 0.024 Mean Signal: 0.028  Take

  12. Slide 12: Specificity Issue: Old v New LLOQ

    Slide 12: Specificity Issue: Old v New LLOQ

    Case 1: A Closer Look at Biomarker Assay Specificity Specificity Issue: Old v New LLOQ New LLOQ = 1.8 pg/ml Old LLOQ = 0.28 pg/ml  Assay has improved specificity for biomarker measurement by reducing background levels and raising LLOQ above noise level  Noise level was determined by using orthogon

  13. Slide 13: Case 2: Developing a Competitive Biomarker Assay

    Slide 13: Case 2: Developing a Competitive Biomarker Assay

    Homebrew Assay Development Case Studies: Case 2: Developing a Competitive Biomarker Assay – Work in Progress

  14. Slide 14: Competitive Biomarker Homebrew Assay

    Slide 14: Competitive Biomarker Homebrew Assay

    Case Study 2: Work in Progress Competitive Biomarker Homebrew Assay  Goal:  Quantify low pg/mL levels of free biomarker in tissue biopsy  Potential challenges of free biomarker quantification include:  Disrupting drug-biomarker complexes through:  Tissue processing  Dilution of sample  Compet

  15. Slide 15: Initial Assay Format: Plate-Based LBA

    Slide 15: Initial Assay Format: Plate-Based LBA

    Case Study 2: Competitive Biomarker Assay – Work in Progress Initial Assay Format Initial assay format: Plate-Based LBA  Signal = Noise for entire plate  Bio-Layer interferometry showed receptor binding non-specifically Alexa 647 biomarker  Bypass complications of using receptor receptor as detec

  16. Slide 16: Why the need for Simoa assay format?

    Slide 16: Why the need for Simoa assay format?

    Case Study 2: Competitive Biomarker Assay – Work in Progress Why the need for Simoa assay format? Revised assay format: ~ 8 ng/mL estimated Competitive LBA sensitivity drug-bound biomarker ruthenylated anti-receptor mAb free biotinylated biomarker receptor  Competitive assay format Streptavidin Pla

  17. Slide 17: Simoa Bead-Based Format

    Slide 17: Simoa Bead-Based Format

    Case Study 2: Competitive Biomarker Assay - Work in Progress Simoa Bead-Based Format receptor-coupled magnetic particle (MP) beads  Simoa sample plate contains: cuvette  Excess biotinylated anti-receptor mAb at constant concentration  Free and drug-bound biomarker

  18. Slide 18: Simoa Bead-Based Format

    Slide 18: Simoa Bead-Based Format

    Case Study 2: Competitive Biomarker Assay - Work in Progress Simoa Bead-Based Format cuvette  Vendor-recommended drug-bound detector range: biotinylated biomarker anti-receptor mAb 100 – 1,000 ng/mL  Initially chose 100 ng/mL biotinylated anti-receptor free biomarker  Vendor-recommended maximum a

  19. Slide 19: Titration of biotinylated anti-receptor mAb

    Slide 19: Titration of biotinylated anti-receptor mAb

    Case Study 2: Competitive Biomarker Assay - Work in Progress Titration of biotinylated anti-receptor mAb  Biotinylated anti-receptor mAb titered to find concentration that yields ~ 20 AEB  No biomarker present, only receptor-coupled beads and biotinylated anti-receptor mAb Biotinylated anti-recept

  20. Slide 20: Titration of biomarker

    Slide 20: Titration of biomarker

    Case Study 2: Competitive Biomarker Assay - Work in Progress Titration of biomarker  Biotinylated anti-receptor mAb:  No decrease in signal with 2,000 pg/mL increasing concentration of  Biomarker: biomarker 2,048 pg/mL – 0.25 pg/mL  Receptor-coupled beads:  No competition? 4 x 106 beads/mL Biom

  21. Slide 21: Simoa Bead-Based Format – No competition?

    Slide 21: Simoa Bead-Based Format – No competition?

    Case Study 2: Competitive Biomarker Assay - Work in Progress Simoa Bead-Based Format – No competition? LBA – Plate-based Simoa – Bead-based  Capture:  Capture:  100 ng/mL biot-receptor  4 x 106 beads/mL  Biomarker:  Biomarker:  1,000 ng/mL  64 pg/mL  2,048 pg/mL  0.25 pg/mL  Detector:  D

  22. Slide 22: Simoa Bead-Based Format – No competition?

    Slide 22: Simoa Bead-Based Format – No competition?

    Case Study 2: Competitive Biomarker Assay - Work in Progress Simoa Bead-Based Format – No competition? I. Too much capture available? II. Sample incubation too short?  4 x 106 beads/mL =  Plate-based: overnight sample 693 ng/mL receptor in cuvette incubation of receptor, anti- Plate-based assay: 1

  23. Slide 23: Simoa Bead-Based Format – Future Plans

    Slide 23: Simoa Bead-Based Format – Future Plans

    Case Study 2: Competitive Biomarker Assay - Work in Progress Simoa Bead-Based Format – Future Plans I. Too much capture available? II. Sample incubation too short? Ways to force competition: Find equilibrium point:  Decrease challenge ratio of  Increase number of cadences receptor to bead during f

  24. Slide 24: Acknowledgements

    Slide 24: Acknowledgements

    Acknowledgements Pfizer PDM-NBE  Sheldon Leung  Alison Joyce  Joe Palandra  Hendrik Neubert  Terri Caiazzo  Boris Gorovits  Chris Lepsy  Marion Kasaian  Martin Dowty  Jenny Zhang Quanterix  Purvish Patel  Huy Le

Source: Internet Archive copy of quanterix.com

More decks from Quanterix Corporation

All 47 Quanterix decks